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INTRODUCTION
Appreciation of the important role of the glomerular
epithelial cell or podocyte in glomerular physiology and
pathology has accelerated in recent years because of
advances in two areas. First, detailed study of a number
of rare syndromes of early-onset nephrotic syndrome has
led to the identification of key genes whose protein
products are specifically expressed by the podocyte and
whose mutation leads to disruption of control of
glomerular permeability. Second, improvements in cell
culture technology have allowed propagation of
differentiated podocytes in vitro, so that these complex
cells can be studied in greater detail in the laboratory.
The purposes of this review are to highlight these recent
advances and focus attention on the podocyte as a key
cell in the normal function of the glomerulus, to consider
ways in which disruption of podocytes can result in
kidney disease, and to suggest the importance of the
podocyte as a target for therapy.
STRUCTURE OF PODOCYTES IN VIVO
The podocyte lies on the outer aspect of the glomerular
capillary and has a complex structure with primary and
secondary cell processes that wrap around the capillary
(Fig. 1). The secondary processes interdigitate; in cross
section, the gaps between these so-called foot processes
are uniform in dimension (Fig. 2) and contain a slit
membrane, which is thought to be an important site of
regulation of glomerular permeability to albumin and
other macromolecules. The cell processes are maintained
by orderly arrangement of actin microfilaments in the
cytoplasm. The podocytes adhere to the outer aspect of
the glomerular basement membrane (GBM) via a group
of proteins known as the focal adhesion complex, and
the cell-cell junctions are characterized by a different
set of adhesion molecules typical of a modified adherens
junction (1). The podocytes are thought to contribute to
synthesis and regulation of the components of the GBM.
GENETIC MUTATIONS LEADING
TO EARLY-ONSET NEPHROTIC
SYNDROME
Congenital nephrotic syndrome of the Finnish type is an
autosomal recessive condition in which devastating
proteinuria is present in homozygotes in the neonatal
Figure 1. Scanning electron micrograph of normal glomerulus.
Figure 2. Transmission electron micrograph of a section of
glomerular capillary wall showing podocyte foot processes on the
outer aspect, separated by uniform filtration slits, each containing
slit membranes ().
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period. The condition carries a high mortality rate and is
usually treated by early bilateral nephrectomy (2). Study
of large affected kindreds in Scandinavia with the use of
modern molecular genetic techniques allowed the
identification by positional cloning of the gene which is
mutated in this condition. The gene has been termed
NPHS1, and its product is called nephrin (3). Nephrin is
located at the slit diaphragm, and its predicted protein
structure suggests that it is a transmembrane protein with
a long cytoplasmic domain that includes numerous
tyrosine residues (suggesting a role in cell signaling).
The precise structure and function of nephrin remains
uncertain, but the fact that homozygous mutations in
nephrin consistently result in severe nephrotic syndrome
provides clear evidence that there is a vital role for this
molecule (and/or other molecules that interact with it)
in the regulation of glomerular permeability to protein.
Similar conclusions can be drawn about other podocyte-
specific proteins identified in similar ways: podocin,
encoded by the gene denoted NPHS2, which is mutated
in autosomal recessive steroid-resistant nephrotic
syndrome (4), and α-actinin IV, mutated in an autosomal
dominant early-onset form of familial focal segmental
glomerulosclerosis (FSGS) (5). Mutations in the gene
encoding WT-1 (also expressed in podocytes) are
associated with Denys-Drash syndrome, in which the
renal features include diffuse mesangial sclerosis and
early-onset kidney failure (6), and with Frasier syndrome,
which also features FSGS (7).
As well as study of rare human genetic variants, further
insights have come from targeted gene mutations in mice.
The importance of nephrin is confirmed by the fact that
in the nephrin “knock-out” mouse, severe early-onset
nephrotic syndrome develops (8). Intriguing observations
were made in mice in which the gene for CD2-associated
protein (CD2AP) had been specifically inactivated. These
animals were expected to show immune abnormalities
because CD2AP is known to be important in T lympho-
cytes  but, unexpectedly, severe early-onset nephrotic
syndrome developed in the mice (9). Subsequently, it
has become apparent that CD2AP is expressed by
podocytes and probably has a role in linking nephrin to
the actin cytoskeleton of these cells (10).
STUDY OF PODOCYTES IN VITRO
Glomerular epithelial cells can be isolated from glomeruli
and grown in primary culture in the laboratory (11).
However, these cells are dedifferentiated and grow in
uniform cobblestone morphology typical of epithelial
cells. They do not have the complex structure typical of
podocytes in vivo and they have a limited life span. This
led to the development of transformed cell lines that have
more growth potential and are easier to work with in the
laboratory because large numbers of clonal cells can be
obtained (12,13). However, these cells do not  develop
the differentiated phenotype of mature podocytes.
Mundel and colleagues (14) addressed this problem by
developing conditionally transformed murine podocyte
cell lines from the “immortomouse”. These cells contain
a temperature-sensitive transgene that is active when the
cells are cultured at 33oC, but when the cells are moved
to 37oC the transgene is inactivated and the cells
differentiate into a phenotype more closely resembling
mature podocytes in vivo. We have used similar
technology to derive human podocyte cell lines (15),
including cells from normal glomeruli and from
glomeruli of kidneys removed because of congenital
nephrotic syndrome. We have obtained cell lines from
patients with mutations in the genes encoding nephrin,
podocin, and WT-1, and these have promise as a useful
resource in understanding the role of these various
proteins in podocyte biology. For example, we have been
able to show that the normal cells express nephrin and
podocin, that nephrin is partially colocalized with the
actin cytoskeleton (16,17), and that treatment of the cells
with puromycin (which causes proteinuria when
administered in vivo) disrupts nephrin and actin and leads
to retraction of cell processes. We also have preliminary
evidence (unpublished observations) that differentiated
normal human podocytes can produce in vitro the
subtypes of type IV collagen and laminin that are typical
components of the GBM, and this will allow us to study
the role of the normal and abnormal podocyte in GBM
production and regulation.
PODOCYTES IN ACQUIRED
GLOMERULAR DISEASE
Most forms of glomerular disease are considered to be
inflammatory and/or autoimmune in origin and are
treated with drugs that have anti-inflammatory and/or
immunosuppressive actions. The podocyte may be villain
or victim in some of these situations: like many other
intrinsic glomerular cell types, podocytes can produce
proinflammatory mediators (18) and express receptors
for cytokines (19) so that the presence of such mediators
in the inflamed glomerulus can induce specific cytokine-
mediated responses in podocytes. However, there is
evidence that in some situations the involvement of the
podocyte in glomerular injury is early and specific, so
that rather than simply being one of the many targets in
the glomerulus that are damaged when there is
inflammation, possibly also contributing to that
inflammation by local production of soluble mediators,
the podocyte may have a more central role. The
implication is that if the effects on podocytes can be
understood and strategies developed to modify them, the
glomerular injury could be interrupted at an early stage.
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This is particularly true in those forms of glomerular
disease in which inflammation is not a prominent feature,
such as minimal change nephropathy (MCN) and FSGS.
Minimal change nephropathy
It is well established that the only morphological change
seen in MCN is disruption of the orderly arrangement of
podocyte foot processes, often referred to as “effacement”
of the foot processes (Fig. 3). Although there has been
controversy about the specificity of this finding with a
study in children with kwashiorkor protein malnutrition
without proteinuria showing similar foot process
effacement (20), the recent observations in congenital
nephrotic syndrome do support the idea that disruption
of podocyte foot process architecture is a key step in the
development of proteinuria. Since MCN is treatment-
sensitive, this implies that the foot process disruption in
that condition is reversible. It has been assumed for many
years that MCN results from an immunological dis-
turbance and that the treatments that are effective in this
condition act by modifying the immune response. There
is an alternative, intriguing possibility: that the
abnormalities of the podocyte are of primary importance
and that drugs such as corticosteroids have direct actions
on the podocyte. We have addressed this by studying the
effects of dexamethasone on podocytes in vitro.
Podocytes express glucocorticoid receptors, and these
are upregulated and translocated in the cell in response
to treatment with dexamethasone (21). We have shown
that dexamethasone promotes proliferation and survival
of podocytes by downregulation of the cell cycle inhibitor
p21, downregulates vascular endothelial growth factor
(VEGF) expression by podocytes, and enhances ex-
pression of tubulin-α and nephrin (22). These data are
consistent with the hypothesis that the efficacy of
corticosteroids in nephrotic syndrome may be at least
partly attributable to direct effects on podocytes.
Focal segmental glomerulosclerosis
The fact that genetically determined forms of FSGS can
result from single gene defects in podocytes raises the
question of whether the more common acquired FSGS
is also primarily caused by podocyte injury. The earliest
morphological change in “idiopathic” FSGS is said to
be the “tip lesion” (23), in which podocytes at the distal
pole of the glomerulus show signs of injury and may
abut on Bowman’s capsule. In kidney transplant
recipients in whom recurrent FSGS develops, there is
the opportunity to observe early changes in the
glomerulus that precede overt glomerular sclerosis. The
earliest histological change is podocyte proliferation (24),
and the injured podocytes show marked alterations in
phenotype (25).
Membranous glomerulonephritis
In membranous glomerulonephritis (MGN), the podocyte
is undoubtedly the “victim” of an immune-mediated
disease. In the animal model of Heymann nephritis,
Figure 3. Scanning electron micrograph of normal glomerulus (A) and glomerulus in minimal change
nephropathy (B) showing "effacement" of foot processes.
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which closely resembles human MGN, antibodies against
megalin, which is expressed on clathrin-coated pits on
the podocyte foot processes, bind to antigen and are
redistributed to form the typical subepithelial immune
deposits. These deposits incite further injury through
activation of complement, and proteinuria develops (26).
In passive Heymann nephritis, there is evidence of gene
activation by nuclear factor-kappaB, predominantly in
podocytes at an early stage, and blockade of this pathway
reduces proteinuria (27). In human MGN, the immune
deposits in the subepithelial space are indistinguishable
from those in Heymann nephritis, but there is no definite
evidence that they result from autoantibodies to intrinsic
glomerular autoantigens. However, even if the reasons
for their appearance in the glomerulus are different in
human MGN compared with Heymann nephritis, it is
likely that similar “downstream” mechanisms of
podocyte injury operate once the deposits are formed.
Progressive glomerulosclerosis
The normal podocyte is a terminally differentiated cell
that is incapable of replicating; therefore injured
podocytes cannot be replaced by regeneration of new
cells. Detailed sequential study of various experimental
models of progressive glomerular injury has led Kriz and
colleagues (28) to propose a unifying hypothesis whereby
podocyte injury and detachment from the GBM leads to
loss of structural stability of the glomerular capillary and
irreversible loss of tuft architecture. According to this
explanation, the unique vulnerability of the podocyte to
injury and its inability to repair or regenerate explain
the importance of this cell in understanding the broadly
similar response of the glomerulus to various different
types of injury, all leading eventually to glomerulo-
sclerosis and loss of the nephron. The importance of
podocyte injury as a predictor of progressive
glomerulosclerosis is supported by studies showing that
the number of podocytes shed into the urine correlates
with disease activity and prognosis in a variety of
inflammatory nephritides (29). Further support is
provided by the observation that podocyte number in
renal biopsy specimens is predictive of prognosis in
glomerular (30) and in nonglomerular (31) diseases.
Human immunodeficiency virus
nephropathy
Infection with human immunodeficiency virus (HIV) is
an increasingly important cause of proteinuric kidney
disease. The most typical form of HIV-associated
nephropathy is characterized by proliferation of
podocytes and the development of collapsing
glomerulopathy in which the podocytes in affected
glomeruli show a dysregulated phenotype (32). There is
now evidence that HIV can directly infect podocytes,
resulting in loss of contact inhibition and podocyte
proliferation (33,34).
Diabetic nephropathy
Podocytes are shed in the urine in patients with diabetic
nephropathy, especially those with macroalbuminuria,
but not in diabetic patients without albuminuria (35).
Podocyte numbers are reduced in type 1 diabetes (36)
and in Pima Indians with type 2 diabetes (37), with the
latter study also showing that podocyte number was a
better predictor of progression than GBM thickness or
any other morphological feature.
PODOCYTES AS TARGETS FOR
THERAPY
The data referred to above concerning the effects of
dexamethasone on human podocytes in vitro, along with
the observations suggesting that MCN and FSGS are
primarily caused by podocyte damage or dysfunction,
suggest that some of the efficacy of corticosteroids in
nephrotic syndrome could be due to direct effects on
podocytes. If so, improved understanding of the
mechanisms and the molecular targets could lead to the
development of more specific forms of therapy without
the unwanted systemic adverse effects of corticosteroids.
At present, it is unknown whether other agents that are
effective in these conditions, such as cyclophosphamide,
cyclosporine, and levamisole, also have effects on
podocytes or if, as has always been assumed, their effects
are solely mediated by alteration of the immune response.
Availability of differentiated human podocytes for study
in the laboratory will allow this question to be tested.
The other form of therapy that is widely used in patients
with persistent proteinuria is blockade of the renin-
angiotensin cascade by the use of angiotensin convert-
ing enzyme inhibitors (ACEi), and, more recently,
angiotensin receptor type 1 antagonists. These drugs are
known to improve the prognosis in proteinuric disease
more effectively than other drugs with similar
antihypertensive efficacy (38); therefore additional
cellular (ie, nonhemodynamic) effects are suspected. It
is therefore intriguing to note that podocytes express
angiotensin receptors and that ACEi and angiotensin
receptor type 1 antagonists exert functional effects on
podocytes in vitro (39). Protective effects of these agents
against podocyte injury have been postulated in patients
with immunoglobulin (Ig) A nephropathy (40) and in
experimental models of diabetic nephropathy (41,42).
Angiotensin converting enzyme inhibitors are one of the
most effective forms of therapy in HIV-associated
nephropathy (43) and if, as discussed above, this
condition is caused by the direct effects of HIV on
podocytes, this may provide the best example yet of an
effective therapy targeted at the podocyte response to
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injury. Another example is in diabetic nephropathy, in
which one of the mediators thought to be important in
pathogenesis is VEGF. Vascular endothelial growth
factor is abundantly expressed by the podocyte and
induced by angiotensin II, leading to the proposal that a
protective mechanism of ACEi in diabetic nephropathy
is through prevention of angiotensin II-mediated VEGF
induction in podocytes (44).
Again, dissection of the precise mechanisms of action
of ACEi and other drugs will be helped by the availability
of podocyte cell lines.
CONCLUSIONS
Podocytes express a number of key proteins that
individually and/or together have a role in the regulation
of glomerular permeability. Acquired nephrotic
syndrome may result from injury to podocytes, and the
inadequacies of podocyte repair mechanisms may
underlie progressive glomerulosclerosis. Current
therapeutic agents may exert part or all of their effects
in glomerular disease by actions on podocytes. By
understanding the normal structure and function of
podocytes, their patterns of gene and protein expression,
and the operative regulatory mechanisms, our ability to
manipulate these complex cells will be enhanced. The
recent availability of differentiated human podocyte cell
lines promises to provide a powerful tool for the study
of these questions, with the real hope of leading to novel
forms of specific therapy for patients with glomerular
disease.
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